Introduction
============

Major depressive disorder (MDD) is a common neuropsychiatric disorder with high prevalence.[@b1-ndt-14-945] Several pathophysiological mechanisms have been proposed to underlie this disorder, such as altered monoamines, increased inflammation, and abnormalities of the hypothalamic--pituitary--adrenal axis.[@b2-ndt-14-945],[@b3-ndt-14-945]

There is growing evidence that glutamatergic signaling may be involved in the pathophysiology of MDD.[@b4-ndt-14-945]--[@b6-ndt-14-945] Dysregulation between the main excitatory glutamatergic and inhibitory gamma-aminobutyric acid-ergic neurotransmission results in cellular damage called "excitotoxicity," and this phenomenon is thought to be the cause of MDD.[@b7-ndt-14-945] Glutamate is one of the major excitatory amino acid neurotransmitters. It plays a major role in brain development, affecting neuronal migration, neuronal differentiation, axon genesis, and neuronal survival.[@b5-ndt-14-945] Under normal conditions, glutamate has a prominent role in synaptic plasticity, learning, and memory, while it is also known to be a potent neuronal excitotoxin, triggering either rapid or delayed neurotoxicity in pathological conditions.[@b4-ndt-14-945] Further, glutamate neurotoxicity results from excessive flux of Ca[@b2-ndt-14-945] via ionotropic receptors, and uncontrolled elevation of intracellular Ca[@b2-ndt-14-945] leads to a cascade of events that contribute to cell damage and death.[@b8-ndt-14-945] Glutamate may also play an important role in the treatment of MDD.[@b9-ndt-14-945],[@b10-ndt-14-945] For example, a significant decrease in blood glutamate levels has been observed in MDD after treatment with antidepressants.[@b11-ndt-14-945],[@b12-ndt-14-945] In a recent meta-analysis of 6 randomized, double-blind, and placebo-controlled trials of ketamine, an N-methyl-[d]{.smallcaps}-aspartate glutamate receptor antagonist, a rapid antidepressant action of ketamine was observed for MDD during 1 week period.[@b13-ndt-14-945] Moreover, a number of studies have shown antidepressant-like effects of glutamatergic agents on behavioral models of MDD.[@b10-ndt-14-945]

Recently, we demonstrated elevated plasma glutamate levels in individuals with MDD, using capillary electrophoresis-time-of-flight mass spectrometry.[@b14-ndt-14-945] However, with regard to peripheral blood glutamate levels in MDD, inconsistent findings have been reported. Although some clinical studies have shown elevated plasma or serum levels of glutamate in MDD,[@b11-ndt-14-945],[@b14-ndt-14-945]--[@b19-ndt-14-945] others did not observe any differences between MDD patients and control subjects.[@b12-ndt-14-945],[@b20-ndt-14-945]--[@b24-ndt-14-945] Besides, it is still unclear whether peripheral blood glutamate levels can reflect brain glutamate levels, since inconsistent findings of central and peripheral glutamate levels in MDD have been reported. A previous postmortem brain study reported increased levels of glutamate in the frontal cortex of patients with MDD.[@b25-ndt-14-945] One previous study demonstrated increased levels of glutamate in the occipital cortex in MDD by using proton magnetic resonance spectroscopy,[@b26-ndt-14-945] while a recent meta-analysis of proton magnetic resonance spectroscopy studies showed no change in glutamate levels in the prefrontal cortex in MDD along with decreased levels of glutamate and glutamine combined.[@b27-ndt-14-945] Another study demonstrated increased levels of glutamate in the cerebrospinal fluid in depressed patients,[@b28-ndt-14-945] whereas other studies have reported decreased levels or no significant differences.[@b29-ndt-14-945]--[@b31-ndt-14-945]

In this study, we conducted a systematic review and meta-analysis of association studies to evaluate whether peripheral blood glutamate levels differed between MDD patients and controls.

Materials and methods
=====================

Study selection process for a meta-analysis
-------------------------------------------

Eligible studies were identified in September 2017 with PubMed and Scopus databases, using the keywords ("Major depressive disorder" OR "depression" OR "depressive disorder") AND ("glutamate" OR "glutamic acid") AND ("serum" OR "plasma"). We also conducted an additional manual search of reference lists in the included publications. Studies meeting the following criteria were included for further meta-analysis: 1) studies assessing peripheral blood (serum or plasma) glutamate levels; 2) studies comparing glutamate levels in MDD patients and control subjects; and 3) studies written in English. Three reviewers (Inoshita M, Tomioka Y, and Watanabe SY) selected the articles independently according to the inclusion criteria. The flow chart of the present study's selection is shown in [Figure S1](#SD1-ndt-14-945){ref-type="supplementary-material"}.

Data extraction
---------------

The following data were extracted from eligible studies: ethnicity, sample size, gender distribution, mean age, mean glutamate concentrations and SD, unit of measure, blood sampling, glutamate assay, medication use, and diagnostic criteria.

Statistical methods
-------------------

Statistical analyses were performed with the "metafor" package in R (version 3.2.3). A meta-analysis of association studies was performed on standardized mean differences (SMD) using the data of sample size and mean and SD of glutamate concentration.[@b32-ndt-14-945],[@b33-ndt-14-945] When the data were presented as a subgroup, we combined these data into one group and calculated the composite mean using the formula: $\text{Composite~mean} = {\sum_{i = 1}^{k}{(n(i) \cdot M(i))/N}}$, where n(*i*) was the sample size of *i*th group, M(*i*) was the mean of *i*th group, *k* was the number of groups, and N was the overall sample size; and composite variance using the formula: Composite variance = (ess+gss)/(N−1), where ess was the overall error sum of squares and gss was the overall group sum of squares. When the data were presented as median and interquartile range, we calculated the mean and SD.[@b34-ndt-14-945] When the data were presented with standard error (SE) of the mean, we calculated the SD as √n×SE, where n was the sample size. Heterogeneity across studies was quantified with the *I*^2^ statistic, with 25%, 50%, and 75% indicating small, moderate, and high levels of heterogeneity, respectively.[@b35-ndt-14-945] If heterogeneity across studies was found, then an inverse-weight variance random-effects model was applied; otherwise, a fixed-effects model was applied. Publication bias was assessed using a regression test for funnel plot asymmetry.[@b36-ndt-14-945] The influence of each selected study on the outcome was assessed using a leave-one-out sensitivity analysis.[@b37-ndt-14-945] Subgroup analyses were performed on the basis of blood sampling (plasma or serum), glutamate assay (high-performance liquid chromatography \[HPLC\] or mass spectroscopy), medication use, fasting or nonfasting sample, and ethnicity (Asian or non-Asian). Meta-regression analysis was performed to examine the effects of age, gender (% male), medication exposure (% medication-received patients), sample size, and published year.

Results
=======

Meta-analysis
-------------

Eleven studies met our inclusion criteria for our meta-analysis[@b12-ndt-14-945],[@b14-ndt-14-945],[@b15-ndt-14-945]--[@b22-ndt-14-945],[@b24-ndt-14-945] ([Figure S1](#SD1-ndt-14-945){ref-type="supplementary-material"}), and the characteristics of these 11 studies are shown in [Table 1](#t1-ndt-14-945){ref-type="table"}. Among the 11 studies, 6 studies reported elevated glutamate levels in MDD,[@b14-ndt-14-945],[@b15-ndt-14-945]--[@b19-ndt-14-945] and the other 5 studies did not find significant differences in glutamate levels between MDD patients and control subjects.[@b12-ndt-14-945],[@b20-ndt-14-945]--[@b22-ndt-14-945],[@b24-ndt-14-945]

When we conducted a meta-analysis of these 12 association studies between blood glutamate levels and MDD from 11 studies in a total of 529 patients with MDD and 590 control participants, a random effects model showed that blood glutamate levels were significantly higher in patients with MDD than in controls, with high heterogeneity (SMD=0.54, 95% CI=0.27--0.82, *p*=8.5×10^−5^, *I*^2^=75.0%, *p*\<0.05, [Figure 1](#f1-ndt-14-945){ref-type="fig"}). A funnel plot analysis indicated no evidence of publication bias in the association studies (*p*\>0.05, [Figure 2](#f2-ndt-14-945){ref-type="fig"}). A leave-one-out sensitivity analysis indicated our result was not driven by any single study (*p*\<0.05, [Table S1](#SD2-ndt-14-945){ref-type="supplementary-material"}).

Subgroup analyses
-----------------

We conducted subgroup analyses according to blood sampling, glutamate assay, medication use, fasting or nonfasting sample, and ethnicity ([Table 2](#t2-ndt-14-945){ref-type="table"}). The pooled SMD from 10 plasma[@b14-ndt-14-945],[@b15-ndt-14-945]--[@b22-ndt-14-945] and 2 serum studies[@b12-ndt-14-945],[@b24-ndt-14-945] was 0.62 (95% CI=0.31--0.93, *p*=1.0×10^−4^, *I*^2^=75.9%, *p*\<0.05) and 0.16 (95% CI=−0.12--0.45, *p*=0.26, *I*^2^=0%, *p*=0.42), respectively. The pooled SMD from 8 studies using HPLC assay12,15--17,19--20,22,24 and 4 studies using MS[@b14-ndt-14-945],[@b18-ndt-14-945],[@b19-ndt-14-945],[@b21-ndt-14-945] was 0.41 (95% CI=0.22--0.60, *p*\<1.0×10^−4^, *I*^2^=28.5%, *p*=0.22) and 0.69 (95% CI=−0.069--1.45, *p*=0.075, *I*^2^=89.7%, *p*\<0.05), respectively. The pooled SMD from 8 studies using medication-free samples[@b12-ndt-14-945],[@b14-ndt-14-945]--[@b16-ndt-14-945],[@b18-ndt-14-945],[@b20-ndt-14-945]--[@b22-ndt-14-945] was 0.59 (95% CI=0.19--1.00, *p*=4.0×10^−3^, *I*^2^=72.9%, *p*\<0.05). The pooled SMD from 4 studies using fasting samples[@b16-ndt-14-945],[@b18-ndt-14-945],[@b21-ndt-14-945],[@b22-ndt-14-945] and 3 studies using nonfasting samples[@b14-ndt-14-945],[@b19-ndt-14-945] was 0.33 (95% CI=0.063--0.59, *p*=0.015, *I*^2^=0%, *p*=0.51) and 0.90 (95% CI=0.031--1.77, *p*=0.042, *I*^2^=94.1%, *p*\<0.05), respectively. The pooled SMD from 7 Asian studies[@b14-ndt-14-945],[@b17-ndt-14-945]--[@b19-ndt-14-945],[@b21-ndt-14-945],[@b24-ndt-14-945] and 5 non-Asian studies[@b12-ndt-14-945],[@b15-ndt-14-945],[@b16-ndt-14-945],[@b20-ndt-14-945],[@b22-ndt-14-945] was 0.58 (95% CI=0.14--1.02, *p*=0.01, *I*^2^=88.6%, *p*\<0.05) and 0.48 (95% CI=0.21--0.76, *p*=6.0×10^−4^, *I*^2^=0%, *p*=0.84), respectively.

Meta-regression analysis
------------------------

When we conducted a meta-regression analysis to examine the effects of age, gender, medication use, sample size, and published year on the glutamate levels, we found no effects of these variables on blood glutamate levels (*p*\>0.05) ([Table 3](#t3-ndt-14-945){ref-type="table"}).

Discussion
==========

This is the first systematic review and meta-analysis of association studies between peripheral blood glutamate levels and MDD, and we demonstrated elevated glutamate levels in MDD in the pooled data set (529 patients with MDD and 590 controls). A high level of heterogeneity was observed in this meta-analysis of all studies (*I*^2^=75.0%). To examine the sources of potential heterogeneity, we subsequently conducted subgroup analyses and a meta-regression analysis.

In the subgroup analyses, we classified studies into those that involved the use of glutamate assays (HPLC or mass spectroscopy) and those that involved food consumption (fasting or nonfasting). We also classified studies into groups based on ethnicity (Asian or non-Asian). We revealed significantly elevated glutamate levels in MDD with remarkably reduced levels of heterogeneity when we considered studies that involved only HPLC assays (SMD=0.41 and *I*^2^=28.5%), only fasting samples (SMD=0.33 and *I*^2^=0%), and only non-Asian samples (SMD=0.48 and *I*^2^=0%). These results suggest that the differences of glutamate assay, food consumption, and ethnicity might contribute to the heterogeneity observed in this study. On the other hand, subgroup analysis using studies involving medication-free samples showed significantly elevated glutamate levels in MDD without reduction of heterogeneity level (*I*^2^=72.9%). However, these results from our subgroup analyses must be viewed with caution because of the small sample size.

In the meta-regression analysis, we found no significant effects of age, gender, medication exposure, sample size, and publication year on blood glutamate levels in MDD patients. However, a significant decrease in blood glutamate levels has been reported in MDD after treatment with antidepressants.[@b11-ndt-14-945],[@b12-ndt-14-945] Besides, a recent study showed significant positive correlations of daily doses of benzodiazepine derivatives and antidepressants with plasma glutamate levels in MDD patients.[@b19-ndt-14-945] These studies suggest that medications, such as antidepressants and benzodiazepines, may affect blood glutamate levels in MDD patients. In this meta-regression analysis of medication exposure, the sample size was small (only two studies[@b17-ndt-14-945],[@b24-ndt-14-945] out of ten used medicated MDD samples), and we were unable to analyze the effect of medication in detail due to insufficient information on drugs used in these included studies. Further studies assessing the effects of medication on blood glutamate levels according to types and dosages of antidepressants will be needed.

Our study has several limitations. First, the sample size was relatively small. Second, there was high heterogeneity among the studies in this meta-analysis. Larger studies with detailed information on participants, such as severity of symptoms, existence of psychosis, types of antidepressants and doses, and metabolic parameters, will be needed to validate our findings and reveal hidden factors that could explain the heterogeneity. Finally, it is still unclear whether peripheral blood glutamate levels can reflect brain levels of glutamate in MDD. Shulman et al[@b38-ndt-14-945] examined the relation between plasma and medial prefrontal cortical glutamate levels in healthy male volunteers, and they found no correlation between them. However, they measured glutamate levels in the limited brain region, and they assessed glutamate levels of healthy subjects, not patients with MDD. Further studies will be needed to examine this relationship between them.

Conclusion
==========

We conducted a systematic review and meta-analysis of association studies between peripheral blood glutamate levels and MDD, and we demonstrated elevated blood glutamate levels in MDD. Our findings suggest that changes in glutamate levels may be implicated in MDD and provide further support for the glutamatergic dysfunction hypothesis of MDD.

Supplementary materials
=======================

###### 

Flow chart of the study selection process.

###### 

Result of leave-one-out sensitivity analysis

  Omitting study                                     SMD    95% CI lower   95% CI upper   *p*-value      *I*^2^ (%)   Q (*p*-value)
  -------------------------------------------------- ------ -------------- -------------- -------------- ------------ ---------------
  Altamura et al,[@b39-ndt-14-945] 1993              0.52   0.25           0.80           2.2×10^−4^     76.9         1.2×10^−4^
  Altamura et al,[@b40-ndt-14-945] 1995              0.56   0.26           0.85           2.4×10^−4^     78.1         \<1.0×10^−4^
  Mauri et al,[@b41-ndt-14-945] 1998                 0.54   0.24           0.84           3.7×10^−4^     78.0         \<1.0×10^−4^
  Maes et al,[@b42-ndt-14-945] 1998                  0.56   0.26           0.86           2.1×10^−4^     78.0         \<1.0×10^−4^
  Mitani et al,[@b43-ndt-14-945] 2006                0.51   0.22           0.79           4.5×10^−4^     75.4         3.3×10^−4^
  Xu et al,[@b44-ndt-14-945] 2012                    0.59   0.31           0.87           \<1.0×10^−4^   75.0         2.1×10^−4^
  Mayoral-Mariles et al,[@b45-ndt-14-945] 2012       0.56   0.27           0.86           2.0×10^−4^     77.8         \<1.0×10^−4^
  Woo et al,[@b46-ndt-14-945] 2015                   0.57   0.27           0.87           1.9×10^−4^     77.5         \<1.0×10^−4^
  Hashimoto et al,[@b47-ndt-14-945] 2016             0.60   0.31           0.88           \<1.0×10^−4^   72.7         5.5×10^−4^
  Umehara et al,[@b48-ndt-14-945] 2017               0.40   0.24           0.55           \<1.0×10^−4^   22.3         0.22
  Ogawa et al,[@b49-ndt-14-945] 2018. sample set A   0.57   0.27           0.88           2.2×10^−4^     72.8         1.4×10^−4^
  Ogawa et al,[@b49-ndt-14-945] 2018. sample set B   0.54   0.24           0.84           4.9×10^−4^     77.0         1.1×10^−4^

**Abbreviation:** SMD, standardized mean difference.
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![RE meta-analysis of association studies between peripheral blood glutamate levels and MDD.\
**Abbreviations:** RE, random effect; MDD, major depressive disorder; SMD, standardized mean difference.](ndt-14-945Fig1){#f1-ndt-14-945}

![Publication bias assessed with funnel plot.\
**Abbreviation:** SMD, standardized mean difference.](ndt-14-945Fig2){#f2-ndt-14-945}

###### 

Characteristics of the included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                              Country   Number of samples (Male, Female)   Mean age (SD)                     Mean glutamate concentration (SD)   Unit of measure          Blood sampling   Measureing method   Medication exposure                                    Fasting information                        Diagnosis
  -------------------------------------------------- --------- ---------------------------------- --------------------------------- ----------------------------------- ------------------------ ---------------- ------------------- ------------------------------------------------------ ------------------------------------------ -------------
  Altamura et al,[@b15-ndt-14-945] 1993              Italy     MDD: 4 (not available)\            MDD: not available\               MDD: 191.86 (272.90)\               nmol/mL                  Plasma           HPLC                Medication-free MDD for at least 3 weeks               No information (drawn at 9:00)             DSM-III-R
                                                               CTRL: 9 (M7F2)                     CTRL: 36.6 (8.3)                  CTRL: 21.58 (7.61)                                                                                                                                                                                  

  Altamura et al,[@b20-ndt-14-945] 1995              USA       MDD: 25 (M15F10)\                  MDD: 31.6 (9.4)\                  MDD: 336 (159)\                     Not available            Plasma           HPLC                Medication-free MDD for at least 8 days                No information (drawn at 9:00)             DSM-III-R
                                                               CTRL: 22 (M13F9)                   CTRL: 28.7 (8.3)                  CTRL: 265 (165)                                                                                                                                                                                     

  Mauri et al,[@b16-ndt-14-945] 1998                 Italy     MDD: 29 (M15F14)\                  MDD: 47.4 (10.9)\                 MDD: 86.05 (147.84)\                nmol/mL                  Plasma           HPLC                Medication-free MDD for at least 4 weeks               Fasting blood                              DSM-IV
                                                               CTRL: 28 (M16F12)                  CTRL: 42.5 (14.2)                 CTRL: 21.97 (23.54)                                                                                                                                                                                 

  Maes et al,[@b12-ndt-14-945] 1998                  Belgium   MDD: 35 (M17F18)\                  MDD: 50.7 (14.4)\                 MDD: 155.66 (57.51)\                μmol/L                   Serum            HPLC                MDD with a washout period of 10 days                   No information (drawn at 7:45)             DSM-III-R
                                                               CTRL: 15 (M10F5)                   CTRL: 47.5 (15.0)                 CTRL: 134 (49)                                                                                                                                                                                      

  Mitani et al,[@b17-ndt-14-945] 2006                Japan     MDD: 23 (M11F12)\                  MDD: 38.0 (11.3)\                 MDD: 94.0 (48.1)\                   nmol/mL                  Plasma           HPLC                6 medication-free MDD and 17 medicated MDD             No information                             DSM-IV
                                                               CTRL: 31 (M17F14)                  CTRL: 41.5 (10.3)                 CTRL: 59.6 (17.7)                                                                                                                                                                                   

  Xu et al,[@b21-ndt-14-945] 2012                    China     MDD: 26 (M7F19)\                   MDD: 32.4 (8.9)\                  MDD: 51.72 (33.67)\                 μmol/L                   Plasma           MS-based method     First-onset treatment-naïve MDD                        Fasting blood                              DSM-IV
                                                               CTRL: 25 (M9F16)                   CTRL: 32.1 (8.2)                  CTRL: 51.72 (33.67)                                                                                                                                                                                 

  Mayoral-Mariles et al,[@b22-ndt-14-945] 2012       Mexico    MDD: 18 (M0F18)\                   MDD: not available for 18 MDD\    MDD: 44.1 (14.0)\                   μM/L                     Plasma           HPLC                Medication-free MDD                                    Fasting blood                              Beck\
                                                               CTRL: 45 (M0F45)                   CTRL: not available for 45 CTRL   CTRL: 39.3 (12.75)                                                                                                                                                                                  Depression\
                                                                                                                                                                                                                                                                                                                                        Inventory

  Woo et al,[@b18-ndt-14-945] 2015                   Korea     MDD: 68 (M16F52)\                  MDD: 65.3 (7.0)\                  MDD: 58.53 (28.63)\                 μmol/L                   Plasma           LC-MS/MS            Medication-free MDD                                    Fasting blood                              DSM-IV
                                                               CTRL: 22 (M4F18)                   CTRL: 68.9 (6.3)                  CTRL: 49.5 (21.0)                                                                                                                                                                                   

  Hashimoto et al,[@b24-ndt-14-945] 2016             Japan     MDD: 70 (M33F37)\                  MDD: 40.2 (9.9)\                  MDD: 4.78 (2.24)\                   μM                       Serum            HPLC                Among 70 MDD, 66 were medicated with antidepressants   No information                             DSM-IV
                                                               CTRL: 78 (M31F47)                  CTRL: 37.2 (9.8)                  CTRL: 4.57 (2.03)                                                                                                                                                                                   

  Umehara et al,[@b14-ndt-14-945] 2017               Japan     MDD: 33 (M10F23)\                  MDD: 47.1 (13.2)\                 MDD: 0.061 (0.030)\                 Relative concentration   Plasma           CE-TOFMS            Medication-free MDD                                    Not fasting blood (drawn in the morning)   DSM-IV
                                                               CTRL: 33 (M10F23)                  CTRL: 46.5 (10.1)                 CTRL: 0.021 (0.0061)                                                                                                                                                                                

  Ogawa et al,[@b19-ndt-14-945] 2018. sample set A   Japan     MDD: 147 (M74F73)\                 MDD: 42.1 (12.1)\                 MDD: 44.53 (24.53)\                 μM                       Plasma           HPLC                Most MDD patients were medicated                       Not fasting blood                          DSM-IV
                                                               CTRL: 217 (M100F117)               CTRL: 41.2 (13.9)                 CTRL: 37.27 (19.04)                                                                                                                                                                                 

  Ogawa et al,[@b19-ndt-14-945] 2018. sample set B   Japan     MDD: 51 (M27F24)\                  MDD: 44.2 (13.4)\                 MDD: 44.55 (18.74)\                 μM                       Plasma           LC/MS               Most MDD patients were medicated                       Not fasting blood                          DSM-IV
                                                               CTRL: 65 (M20F45)                  CTRL: 43.4 (13.4)                 CTRL: 34.52 (13.23)                                                                                                                                                                                 
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** MDD, major depressive disorder; CTRL, control; HPLC, high-performance liquid chromatography; *DSM, Diagnostic and Statistical Manual of Mental Disorders*; LC-MS/MS, liquid chromatography--tandem mass spectrometry; CE-TOFMS, capillary electrophoresis-time-of-flight mass spectrometry.

###### 

Results of subgroup analyses analysis of association studies between peripheral blood glutamate levels and MDD

  Variables          Number of association studies   Subgroup analysis   Heterogeneity                            
  ------------------ ------------------------------- ------------------- --------------- ------ ---------- ------ --------------
  Blood sampling                                                                                                  
   Plasma            10                              0.62                0.31            0.93   0.0001     75.9   2.9×10^−4^
   Serum             2                               0.16                −0.12           0.45   0.26       0      0.42
  Glutamate assay                                                                                                 
   HPLC              8                               0.41                0.22            0.60   \<0.0001   28.5   0.22
   MS                4                               0.69                −0.069          1.45   0.075      89.7   \<1.0×10^−4^
  Medication                                                                                                      
   Medication free   8                               0.59                0.19            1.00   0.004      72.9   6.8×10^−4^
  Food consumption                                                                                                
   Fasting           4                               0.33                0.063           0.59   0.015      0      0.51
   Not fasting       3                               0.90                0.031           1.77   0.042      94.1   \<1.0×10^−4^
  Ethnicity                                                                                                       
   Asian             7                               0.58                0.14            1.02   0.01       88.6   \<1.0×10^−4^
   Non-Asian         5                               0.48                0.21            0.76   0.0006     0      0.84

**Abbreviations:** MDD, major depressive disorder; SMD, standardized mean difference; HPLC, high-performance liquid chromatography; MS, mass spectroscopy.

###### 

Result of a meta-regression analysis in patients with MDD and controls

  Moderator                                              Number of association studies   Meta-regression analysis   Heterogeneity                          
  ------------------------------------------------------ ------------------------------- -------------------------- --------------- -------- ------ ------ --------------
  Age (mean year)                                        10                              0.0078                     −0.027          0.042    0.66   82.3   \<1.0×10^−4^
  Gender (% male)                                        11                              0.0006                     −0.018          0.019    0.95   79.7   \<1.0×10^−4^
  Medication exposure (% medication-received patients)   10                              −0.0018                    −0.012          0.0083   0.73   74.8   1.2×10^−4^
  Sample size                                            12                              −0.0012                    −0.0041         0.0017   0.42   72.2   2.4×10^−4^
  Published year                                         12                              −0.0018                    −0.035          0.032    0.92   77.3   \<1.0×10^−4^

**Abbreviation:** MDD, major depressive disorder.
